表 1.

ADCs治疗晚期NSCLC的临床研究

Clinical trials of ADCs in the treatment of advanced NSCLC

ADCs	Clinical trial	Reference	Efficacy	Adverse events
ADCs: antibody-drug conjugates; ORR: objective response rate; PFS: progression-free survival; OS: overall survival; DOR: duration of response; CBR: clinical benefit rate; DCR: disease control rate.
T-DM1	UMIN000017709	Hotta K, 2018[14]	ORR: 6.7%; PFS: 2.0 mon; OS: 10.9 mon	Grade 3 or 4 thrombocytopenia (40%) and hepatotoxicity (20%), without any treatment-related deaths
DS-8201a	NCT03505710	Li BT, 2021[22]	ORR: 55%; DOR: 9.3 mon; PFS: 8.2 mon; OS: 17.8 mon	Grade 3 or higher neutropenia (19%) and adjudicated drug-related interstitial lung disease (26%) resulted in death in 2 patients
IMMU-132	NCT01631552	Heist RS, 2017[26]	ORR: 19%; DOR: 6.0 mon; CBR: 43%	Grade 3 or higher neutropenia (28%), diarrhea (7%), nausea (7%), fatigue (6%), and febrile neutropenia (4%)
ABBV-399	NCT03311477	Fujiwara Y, 2021[32]	ORR: 23%; DOR: 8.7 mon; PFS: 5.2 mon	Grade 3 or higher decreased neutrophil count and hypoalbuminemia (22% each)
PF-06647020	NCT02222922	Jasgit CS, 2018[37]	ORR: 16%; DCR: 56%; DOR: 5.8 mon; PFS: 2.9 mon	Grade 1 or 2 nausea, alopecia, fatigue, headache, neutropenia, and vomiting, without any treatment-related deaths